TS2 TECH • DAILY MODEL PORTFOLIO
Stocks to Buy Today
Five U.S.-listed stocks were ranked for Thursday, July 30. The latest earnings and forward guidance are the main factors in the rankings. Large opening gaps are viewed as a negative for entry and do not contribute positively to the score.
Selective • limit orders
05:57 ET • premarket
-1.52%
-1.74%
about 5.24%
above $92
Microsoft is driving a slight rebound in futures. With Apple and Amazon set to report after the close, index volatility remains elevated.
24% weight
Microsoft
NASDAQ: MSFT
94 / 100
Azure’s growth picked up speed, the commercial backlog saw significant expansion, and the sales outlook for next quarter exceeded forecasts. Shares are set for a strong premarket rise. Placing a limit order close to the projected range is advised over chasing the initial jump.
Fourth-quarter revenue reached $90.0 billion, up 18%. Adjusted earnings per share came in at $4.74, a 23% increase. Azure revenue rose 43%.
Microsoft projects Q1 revenue at a midpoint of $90.4 billion, with Azure growing roughly 45% and its commercial backlog reaching $678 billion.
Premarket reference stands at $422.88, roughly 24.5 times projected FY2026 adjusted EPS. The current consensus target is around $556 and continues to be updated.
Initiate positions between $414 and $423, consider adding between $404 and $410, and avoid buying above $430.
Backlog conversion, growth in Copilot seats, and cash returns driven by AI capacity investments.
included unusual investment gains, while long-term interest rates are rising.
22% weight
L3Harris Technologies
NYSE: LHX
90 / 100
Orders, backlog, margins, and free cash flow all improved during the quarter. Shares initially rose after hours but gave up gains before the market opened, suggesting investors are weighing the strength of the company’s updated outlook.
Orders reached $7.3 billion, with revenue up 8% to $5.9 billion. Earnings per share rose 28% to $3.13, while free cash flow increased 37% to $771 million.
For 2026, revenue is projected between $23.2 billion and $23.7 billion, with EPS in the range of $11.80 to $12.00. The company reports a record backlog of $42 billion.
Premarket trading points to around $290, down about 2.5%. Shares are valued at approximately 24.4 times the projected EPS midpoint. The consensus target stands near $375, about 29% above current levels.
First tranche: $286–$292. Consider adding at $276–$282. Avoid pursuing above $300.
Growth in missile production, new contract wins, and progress converting a record backlog.
quarterly margins even when long-term demand remains firm.
20% weight
Xylem
NYSE: XYL
89 / 100
Orders grew at a much faster pace than revenue, while margins widened and profit guidance improved. The stock provides indirect exposure to data center, power, and semiconductor spending, without the risk of another major opening surge.
Orders reached $3.1 billion, up 42%. Revenue came in at $2.3 billion, a 2% increase. Adjusted EPS rose 16% to $1.46, while the EBITDA margin stood at 23.3%.
Projected 2026 revenue is around $9.2 billion, with EPS estimated between $5.55 and $5.70. EBITDA margin is expected to range from 23.1% to 23.5%, and free cash flow margin between 10.2% and 11.0%.
Shares closed at $122.13, trading at around 21.7 times the projected EPS midpoint. Analysts have set a consensus price target of $154, which is about 26% above current levels.
Initial tranche at $119 to $124; add between $114 and $117; reconsider position if shares fall below $110
Order conversions and new water projects linked to data centers, power generation, and industrial clients.
budgets and uneven regional demand can delay the order-to-sales conversion.
18% weight
Lam Research
NASDAQ: LRCX
87 / 100
Lam reported record profit margins and provided a September-quarter outlook that surpassed previous consensus estimates. The company’s performance is robust. However, the reduced weighting takes into account the volatility in the semiconductor sector, as shares opened about 8% higher.
Revenue reached $6.72 billion, with adjusted EPS at $1.82. The non-GAAP gross margin was 52.0%, and operating margin stood at 38.4%.
Revenue for September came in at $8.1 billion, plus or minus $400 million. Earnings per share were $2.15, within a $0.15 range. The operating margin was 39.5%, with a 1-point variance.
The midpoint of the revenue guidance is roughly 14% higher than the previous consensus, while the EPS guidance midpoint comes in about 17% above expectations.
The premarket reference stands at $272.97, with the consensus price target near $375—about 37% higher. The target set continues to be updated.
Buy the first tranche between $263 and $273, add positions from $250 to $258, but avoid buying above $280.
Performance in the September quarter, along with memory investment and customer spending on advanced-node equipment.
customer concentration and the semiconductor cycle can change estimates quickly.
16% weight
GE HealthCare
NASDAQ: GEHC
84 / 100
Record orders and a strong backlog provide better visibility, while the stock’s earnings multiple is still lower than the other four holdings. After Wednesday’s 12% jump, the near-term upside is limited, so we’ll initiate a position only if the price pulls back.
Revenue rose 5.7% to $5.3 billion, with adjusted EPS at $1.13. Organic orders increased 11.1%. The book-to-bill ratio was 1.15, and backlog stood at $23.9 billion.
The company expects organic revenue to rise 3% to 4%, with adjusted earnings per share projected between $4.80 and $5.00. Free cash flow is estimated at around $1.6 billion.
Shares closed at $71.90, trading at about 14.7 times the guided EPS midpoint. The consensus price target stands at $80.50, indicating an upside of roughly 12%.
Initiate with a first tranche at $68.50–$71.50; consider adding between $64 and $67; avoid buying above $73.
Key topics include backlog conversion, memory chip expenses, and the ongoing strategic review of Patient Care Solutions.
fell 40 basis points, and Patient Care Solutions revenue declined sharply.
24%
22%
20%
18%
16%
35%
20%
20%
15%
10%
Scores reflect today’s available opportunities, ranking them rather than indicating expected percentage returns.
Use three limit-order tranches. Do not convert an earnings gap into a market order.
A stock opening over 5% above its reference price isn’t chased on its first day. Review your portfolio after Apple and Amazon report earnings tonight.
NASDAQ: SBUX
WAIT FOR A CHEAPER ENTRY
Comparable sales climbed 7.9% and the company raised its guidance, yet shares now trade at about 42 times the updated EPS midpoint in premarket action.
NASDAQ: FTNT
DO NOT CHASE THE GAP
Revenue rose 26%, with free cash flow totaling $966 million. At nearly $169, shares trade at roughly 49 times the midpoint of the company’s 2026 EPS forecast.
NYSE: F
TACTICAL WATCH
The company raised its guidance, and Citi upgraded the stock to Buy with a $20 price target. Most analysts see the stock trading close to current levels, as significant EV losses persist.
NASDAQ: AAPL • NASDAQ: AMZN
WAIT FOR RESULTS
Both companies are set to report after today’s close. The portfolio is steering clear of new binary event risks ahead of the results.
7.3 / 10
High. While earnings support is solid, Microsoft and Lam Research both show opening gaps of around 8%, with rates and oil prices still posing headwinds.
Stocks closed sharply lower on Wednesday. The 30-year Treasury yield climbed to 5.24%, its highest point since 2007, while oil topped $92 a barrel. These levels threaten to erase growth-stock gains, despite strong earnings.